EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Empagliflozin And Metformin Hydrochloride patents expire, and when can generic versions of Empagliflozin And Metformin Hydrochloride launch?
Empagliflozin And Metformin Hydrochloride is a drug marketed by Zydus Pharms and is included in one NDA.
The generic ingredient in EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE?
- What are the global sales for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE?
- What is Average Wholesale Price for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE?
Summary for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 62 |
Patent Applications: | 4 |
Formulation / Manufacturing: | see details |
DailyMed Link: | EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE at DailyMed |
![EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE drug patent expirations Drug patent expirations by year for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE](/p/graph/s/t/EMPAGLIFLOZIN_AND_METFORMIN_HYDROCHLORIDE-patent-expirations.png)
Recent Clinical Trials for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tanta University | Phase 3 |
Handok Inc. | Phase 3 |
Karolinska University Hospital | N/A |
See all EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE clinical trials